Nichola Cruickshanks

发表

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma

E. Petricoin, D. Schiff, J. Wulfkuhle, 2018, Clinical Cancer Research.

The p53 Pathway in Glioblastoma

N. Cruickshanks, R. Abounader, Fang Yuan, 2018, Cancers.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

Anna C. Salzberg, Y. Rojanasakul, M. Kirsch‐Volders, 2015, Carcinogenesis.

Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

P. Dent, S. Grant, N. Cruickshanks, 2014, Molecular Cancer Therapeutics.

PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells

M. Malkin, P. Dent, S. Grant, 2014, Cancer biology & therapy.

Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells

P. Fisher, P. Dent, S. Grant, 2014, Molecular Pharmacology.

OSU-03012 interacts with lapatinib to kill brain cancer cells

P. Dent, S. Grant, N. Cruickshanks, 2012, Cancer biology & therapy.

Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma

T. Dawson, N. Cruickshanks, R. Lea, 2007, Brain Research.

Noncoding RNAs in Glioblastoma

Anindya Dutta, D. Schiff, N. Cruickshanks, 2017 .

Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

William H. Bisson, C. Naus, A. Colacci, 2015, Carcinogenesis.

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling

S. Spiegel, P. Dent, S. Grant, 2012, Cancer biology & therapy.

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma

N. Cruickshanks, R. Abounader, Fang Yuan, 2017, Cancers.

PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types

S. Spiegel, P. Dent, N. Cruickshanks, 2015, Journal of cellular physiology.

Differential regulation of autophagy and cell viability by ceramide species

S. Spiegel, P. Dent, N. Cruickshanks, 2015, Cancer biology & therapy.

p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression

H. Zong, N. Cruickshanks, R. Abounader, 2018, Glia.

Targetable T-type Calcium Channels Drive Glioblastoma.

E. Petricoin, D. Schiff, J. Wulfkuhle, 2017, Cancer research.

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

P. Dent, S. Grant, N. Cruickshanks, 2013, Cancer biology & therapy.

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells

P. Dent, N. Cruickshanks, L. Booth, 2015, Journal of cellular physiology.

Current advances in ER stress intervention therapies

P. Fisher, P. Dent, S. Grant, 2012 .

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

P. Dent, S. Grant, Yun Dai, 2013, Cancer biology & therapy.

Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells

P. Fisher, P. Dent, S. Grant, 2013, Cancer biology & therapy.

A Serotype 5/3 Adenovirus Expressing MDA-7/IL-24 Infects Renal Carcinoma Cells and Promotes Toxicity of Agents That Increase Ros and Ceramide Levels

P. Fisher, S. Spiegel, P. Dent, 2011, Molecular Pharmacology.

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

P. Dent, A. Yacoub, S. Grant, 2011, Cancer biology & therapy.

The role of cell signalling in the crosstalk between autophagy and apoptosis.

P. Dent, N. Cruickshanks, L. Booth, 2014, Cellular signalling.

Regulation of dimethyl-fumarate toxicity by proteasome inhibitors

P. Dent, N. Cruickshanks, Jane L. Roberts, 2014, Cancer biology & therapy.

Can hsp90α-Targeted siRNA Combined With TMZ Be a Future Therapy for Glioma?

N. Cruickshanks, Rahima Patel, A. Shervington, 2010, Cancer investigation.

Can The Lack of HSP90α Protein in Brain Normal Tissue and Cell Lines, Rationalise it as a Possible Therapeutic Target for Gliomas?

T. Dawson, N. Cruickshanks, R. Lea, 2008, Cancer investigation.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

P. Fisher, K. Nephew, P. Dent, 2011, Autophagy.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.

P. Fisher, K. Nephew, P. Dent, 2011, Cancer research.

Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA

P. Fisher, P. Dent, S. Grant, 2012, Molecular Pharmacology.

Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells

P. Dent, S. Grant, N. Cruickshanks, 2013, Molecular Pharmacology.

Lapatinib and Obatoclax Kill Breast Cancer Cells through Reactive Oxygen Species-Dependent Endoplasmic Reticulum Stress

P. Dent, S. Grant, Yong Tang, 2012, Molecular Pharmacology.

The role of cell signalling in the crosstalk between autophagy and apoptosis.

P. Dent, Hossein A. Hamed, S. Tavallai, 2014, Cellular signalling.

Glioma: What is the role of c-Myc, hsp90 and telomerase?

N. Cruickshanks, R. Lea, A. Shervington, 2006, Molecular and Cellular Biochemistry.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

William H. Bisson, Anna C. Salzberg, Y. Rojanasakul, 2015, Carcinogenesis.

Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: Replicative immortality

R. Nahta, L. Memeo, W. Rathmell, 2023 .

Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1

P. Fisher, P. Dent, S. Grant, 2012, Molecular Pharmacology.